Does APALUTAMIDE Cause Hormone-refractory prostate cancer? 9 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 9 reports of Hormone-refractory prostate cancer have been filed in association with APALUTAMIDE (ERLEADA). This represents 0.1% of all adverse event reports for APALUTAMIDE.
9
Reports of Hormone-refractory prostate cancer with APALUTAMIDE
0.1%
of all APALUTAMIDE reports
2
Deaths
2
Hospitalizations
How Dangerous Is Hormone-refractory prostate cancer From APALUTAMIDE?
Of the 9 reports, 2 (22.2%) resulted in death, 2 (22.2%) required hospitalization, and 1 (11.1%) were considered life-threatening.
Is Hormone-refractory prostate cancer Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for APALUTAMIDE. However, 9 reports have been filed with the FAERS database.
What Other Side Effects Does APALUTAMIDE Cause?
Rash (1,117)
Death (1,008)
Fatigue (824)
Hot flush (532)
Product dose omission issue (384)
Diarrhoea (317)
Asthenia (303)
Dizziness (294)
Fall (268)
Off label use (257)
What Other Drugs Cause Hormone-refractory prostate cancer?
RADIUM RA-223 DICHLORIDE (441)
LEUPROLIDE (180)
DOCETAXEL (123)
ENZALUTAMIDE (120)
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN (110)
DAROLUTAMIDE (104)
ABIRATERONE (83)
PREDNISONE (58)
CABAZITAXEL (57)
BICALUTAMIDE (50)
Which APALUTAMIDE Alternatives Have Lower Hormone-refractory prostate cancer Risk?
APALUTAMIDE vs APATINIB
APALUTAMIDE vs APIDRA
APALUTAMIDE vs APIDRA SOLOSTAR
APALUTAMIDE vs APIXABAN
APALUTAMIDE vs APLISOL DIAGNOSTIC ANTIGEN